secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001493152-23-033356
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals enters consulting & amended services agreements with related party Epiq Scripts
--------------------------------------------------------------------------------

- Engaged Epiq Scripts for global pharmacy consulting outside US; $65K upfront plus per-pill declining fees over 5 years (amounts redacted).
- Amended MSA: added right of first negotiation/refusal for new jurisdictions and a 1% non-use fee on gross sales if services transferred.
- Epiq Scripts is 51% owned by CEO Jacob D. Cohen; the agreements are related-party transactions.
- No consulting payments until first commercial sale outside US; no immediate revenue impact expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/0001493152-23-033356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer